Sanofi Expected to Post Q2 2024 Earnings of $0.90 Per Share (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) – Equities research analysts at Leerink Partnrs cut their Q2 2024 EPS estimates for shares of Sanofi in a report released on Thursday, April 25th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings of $0.90 per share for the quarter, down from their previous estimate of $0.91. The consensus estimate for Sanofi’s current full-year earnings is $4.09 per share. Leerink Partnrs also issued estimates for Sanofi’s Q4 2024 earnings at $0.87 EPS, FY2026 earnings at $4.95 EPS and FY2027 earnings at $5.47 EPS.

Several other equities analysts have also commented on the company. TheStreet lowered Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Morgan Stanley assumed coverage on Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price for the company. Finally, StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $55.00.

Sanofi Stock Performance

NASDAQ:SNY opened at $49.23 on Monday. The company has a fifty day simple moving average of $47.82 and a two-hundred day simple moving average of $48.25. The company has a market cap of $124.53 billion, a price-to-earnings ratio of 24.74, a price-to-earnings-growth ratio of 1.48 and a beta of 0.61. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. Sanofi has a 52 week low of $42.63 and a 52 week high of $55.93.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The firm had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a net margin of 10.52% and a return on equity of 19.69%.

Institutional Trading of Sanofi

A number of institutional investors have recently modified their holdings of the business. Cardinal Capital Management boosted its position in Sanofi by 0.3% during the fourth quarter. Cardinal Capital Management now owns 58,854 shares of the company’s stock worth $2,927,000 after purchasing an additional 201 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in Sanofi by 3.4% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock worth $325,000 after purchasing an additional 216 shares in the last quarter. Wynn Capital LLC boosted its position in Sanofi by 4.5% during the first quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock worth $256,000 after purchasing an additional 226 shares in the last quarter. Sage Rhino Capital LLC boosted its position in Sanofi by 2.8% during the third quarter. Sage Rhino Capital LLC now owns 8,722 shares of the company’s stock worth $468,000 after purchasing an additional 240 shares in the last quarter. Finally, Angeles Investment Advisors LLC boosted its position in Sanofi by 2.1% during the fourth quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company’s stock worth $598,000 after purchasing an additional 244 shares in the last quarter. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be paid a $1.478 dividend. The ex-dividend date is Thursday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. Sanofi’s payout ratio is 69.35%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.